1. INTRODUCTION
1.1 DEFINITION
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.2.2.1 ASSUMPTIONS
1.2.2.2 LIMITATIONS
1.3 MARKET STRUCTURE:
2. RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH:
3. MARKET DYNAMICS
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 MACROECONOMIC INDICATORS
4. MARKET FACTOR ANALYSIS
4.1 PORTERS FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
4.4 THREAT OF NEW ENTRANTS
4.5 THREAT OF SUBSTITUTES
4.6 INTENSITY OF RIVALRY
5. GLOBAL LEPROSY TREATMENT MARKET, BY DRUG CLASS
5.1 SULFONE
5.2 PHENAZINE DERIVATIVE
5.3 ANTI-TUBERCULAR DRUGS
5.4 OTHERS
6. GLOBAL LEPROSY TREATMENT MARKET, BY DISEASE TYPE
6.1 PAUCIBACILLARY LEPROSY
6.2 MULTIBACILLARY LEPROSY
7. GLOBAL LEPROSY TREATMENT MARKET, BY MARKET CHANNEL
7.1 PRIVATE
7.2 CONTRACT
7.3 OTHERS
8. GLOBAL LEPROSY TREATMENT MARKET, BY REGION
8.1 NORTH AMERICA
8.1.1 INTRODUCTION
8.2 EUROPE
8.2.1 INTRODUCTION
8.3 ASIA-PACIFIC
8.3.1 INTRODUCTION
8.4 MIDDLE EAST & AFRICA
8.4.1 INTRODUCTION
9. COMPETITIVE LANDSCAPE
9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
9.1.1 STRATEGIC PARTNERSHIP
9.1.2 MERGER & ACQUISITION
10. COMPANY PROFILE
10.1 GLAXO SMITHCLINE
10.1.1 OVERVIEW
10.1.2 PRODUCT OVERVIEW
10.1.3 FINANCIALS
10.1.4 KEY DEVELOPMENTS
10.2 SYSTOPIC LABORATORIES PVT. LTD.
10.2.1 OVERVIEW
10.2.2 PRODUCT OVERVIEW
10.2.3 FINANCIALS
10.2.4 KEY DEVELOPMENTS
10.3 CADILA PHARMACEUTICALS
10.3.1 OVERVIEW
10.3.2 PRODUCT OVERVIEW
10.3.3 FINANCIALS
10.3.4 KEY DEVELOPMENT
10.4 ACME PHARMACEUTICALS
10.4.1 OVERVIEW
10.4.2 PRODUCT OVERVIEW
10.4.3 FINANCIALS
10.4.4 KEY DEVELOPMENTS
10.5 MACLEODS PHARMACEUTICALS
10.5.1 OVERVIEW
10.5.2 PRODUCT OVERVIEW
10.5.3 FINANCIALS
10.5.4 KEY DEVELOPMENTS
10.6 NOVARTIS INTERNATIONAL AG
10.6.1 OVERVIEW
10.6.2 PRODUCT OVERVIEW
10.6.3 FINANCIALS
10.6.4 KEY DEVELOPMENTS
10.7 ASTRA ZENECA
10.7.1 OVERVIEW
10.7.2 PRODUCT OVERVIEW
10.7.3 FINANCIALS
10.7.4 KEY DEVELOPMENTS
10.8 LARK LABORATORIES LTD.
10.8.1 OVERVIEW
10.8.2 PRODUCT OVERVIEW
10.8.3 FINANCIALS
10.8.4 KEY DEVELOPMENTS
10.9 OTHERS
11. CONCLUSION
11.1 KEY FINDINGS
11.1.1 FROM CEO’S VIEWPOINT
11.1.2 UNMET NEEDS OF THE MARKET
11.2 KEY COMPANIES TO WATCH
11.3 PREDICTION OF LEPROSY TREATMENT INDUSTRY
12. APPENDIX